Is metformin use associated with cognitive, physical and cardiovascular outcomes in older adults with type 2 diabetes? A secondary analysis of the SCOPE multicentre prospective cohort study.
Key claim: Metformin use in community-dwelling adults aged 75 and older with type 2 diabetes was associated with stable cognitive scores and a 50% reduction in cardiovascular events and mortality over two years, without affecting physical function.
Abstract
ABSTRACT: OBJECTIVES: Type 2 diabetes (T2D) is common in older adults and often coexists with reduced kidney function, which increases the risk of cognitive decline and cardiovascular events. The aim was to examine the association between metformin use and cognitive function, physical function, disability, cardiovascular events and all-cause mortality in older adults with T2D. DESIGN: Secondary prospective analysis of the Screening for Chronic Kidney Disease among Older People across Europe (SCOPE) study (conducted between August 2016 and August 2018), a multicentre 2-year study in which metformin exposure was not randomised. Regression models were used to evaluate associations between metformin use and study outcomes. SETTING: Community-based multicentre study conducted across Europe. PARTICIPANTS: The analysis included 412 community-dwelling older adults (≥75 years) with T2D enrolled in the SCOPE study (mean age 80.2 years, 46.1% women). OUTCOME MEASURES: Cognitive function assessed by the Mini-Mental State Examination (MMSE), physical performance assessed by the Short Physical Performance Battery, handgrip strength, functional status and disability (basic activities of daily living (BADL) and instrumental activities of daily living (IADL)), cardiovascular events and mortality. RESULTS: Metformin users maintained stable MMSE scores while a slight decrease in MMSE score was observed in non-users. Significant baseline imbalances existed: non-metformin users had lower estimated glomerular filtration rate (44.8 vs 56.3 mL/min) and higher heart failure prevalence (28.9% vs 13.5%). At 2 years, metformin users maintained stable MMSE scores, while non-users showed a slight decrease (0.0 vs −0.7; p<0.001); however, this statistical difference is very small and unlikely to be clinically meaningful in the short term. Additionally, metformin use was associated with a lower risk of cardiovascular events and cardiovascular mortality at 2 years (HR: 0.50; 95% CI 0.30 to 0.84). There were no significant differences in physical function and handgrip strength, BADL or IADL. CONCLUSIONS: Metformin use was associated with preserved cognitive performance over 2 years, while a slight decline was observed among non-users. Additionally, metformin was associated with lower risk of cardiovascular events and mortality. However, given the 2-year duration of the study, further research is needed to confirm these findings, particularly in relation to cognitive decline and dementia, which have a long prodromal phase.
Why this matters
Metformin use in community-dwelling adults aged 75 and older with type 2 diabetes was associated with stable cognitive scores and a 50% reduction in cardiovascular events and mortality over two years, without affecting physical function.